Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ras-related protein Rab-4A (RAB4A)
- Target
- RAB4A
- Molecular classification
- Small GTPase, Member of Ras superfamily, Protein involved in membrane trafficking
01
Overview
Ras-related protein Rab-4A (RAB4A) is a member of the Ras superfamily of small GTPases that are essential regulators of intracellular membrane trafficking. RAB4A is primarily associated with early endosomes and mediates sorting and recycling of internalized receptors back to the plasma membrane. The active, GTP-bound form of Rab-4A recruits various downstream effectors that facilitate vesicle formation, movement, docking, and fusion. Its biological roles span receptor trafficking, antigen processing, cellular signaling, regulation of VEGFR2-mediated pathways, and platelet granule release. Mechanistically, alterations in RAB4A are implicated in various diseases, including cancer and neurological disorders, making it an attractive target for research and potential therapeutic intervention[1][2][7][4][6].
- Other names
- RAB4ARAB4HRES-1/RAB4HRES-1HRES1HTLV-1 related endogenous sequenceRas-related protein Rab-4A
02
Mechanism of action
Drugs hypothetically targeting RAB4A would impact endosomal trafficking, membrane recycling, or receptor surface expression, leading to modulation of receptor-mediated signaling pathways (e.g., VEGFR2)
03
Biological functions
Regulation of membrane traffickingEndocytosis and receptor recyclingVesicle formation, movement, tethering, fusionAntigen processing and presentationRegulation of VEGFR2 signaling via endosomal traffickingRegulation of platelet alpha-granule releaseATPase binding activity
04
Disease associations
Cancer: Downregulation of RAB4A shown to inhibit progression of gastric cancerNeurological diseases: Implicated in Pontocerebellar Hypoplasia, Type 2E and Charcot-Marie-Tooth Disease Type 4DOther possible roles indicated by ongoing research but not fully established
05
Safety considerations
Potential therapeutic challenges could include widespread cellular involvement, leading to off-target effects on general vesicular trafficking, receptor recycling, or antigen presentation. However, no specific adverse safety concerns are documented in the search results.
06
Interacting drugs
No approved drugs are directly listed as interacting with RAB4A in the referenced results. However, its regulatory role in receptor recycling and trafficking may have indirect implications for targeted therapies (e.g., drugs affecting VEGFR2 signaling)
07
Biomarkers
RAB4A expression and activity status have potential utility as biomarkers for certain cancers (e.g., gastric cancer)
Beyond the preview
Go deeper on Ras-related protein Rab-4A (RAB4A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ras-related protein Rab-4A (RAB4A).